is a high-tech large-scale joint-stock enterprise integrating animal drug research and development, production, sales, and after-sales service
Differential distribution of somatostatin sst2 receptor splice variants in rat gastric mucosa
A notable development is the launch of Wegovy by Novo Nordisk A/S in March 2024, the first once-weekly GLP-1 therapy designed to manage weight effectively, showcasing a safe and convenient approach for patients
Some studies suggest that the impact of GLP-1 RA on OSA is mainly through reducing AHI [51, 53, 81]
It is synthesized from lysine and methionine in the liver, kidneys, and brain
Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) are contraindicated from GLP-1 therapy